Chalasani, Naga

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 7,239

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 3,327

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial

Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 2,237

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., et al. (2021) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,146

Drug-induced liver injury

Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers

Drug-Induced Hepatotoxicity and ProtectionPharmacovigilance and Adverse Drug Reactions

Cited by 924

ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury

Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology

Drug-Induced Hepatotoxicity and ProtectionComplementary and Alternative Medicine Studies

Cited by 860

Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study

Vilar-Gomez, E., Calzadilla-Bertot, L., Wai-Sun Wong, V., Castellanos, M., Aller-de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quiñones Sanz, M., Conde-Martin, A. F., et al. (2018) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 806

Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct

Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety

Drug-Induced Hepatotoxicity and ProtectionPharmacovigilance and Adverse Drug Reactions

Cited by 486

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity

Chalasani, N., Aljadhey, H., Kesterson, J., Murray, M. D., & Hall, S. D. (2004) · Gastroenterology

Drug-Induced Hepatotoxicity and ProtectionLipoproteins and Cardiovascular Health

Cited by 441

ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury

Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & on behalf of the Practice Parameters Committee of the American College of Gastroenterology (2021) · American Journal of Gastroenterology

Drug-Induced Hepatotoxicity and ProtectionLiver Diseases and Immunity

Cited by 430

Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial

Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., et al. (2021) · Hepatology

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 379

Association of histologic disease activity with progression of nonalcoholic fatty liver disease

Kleiner, D. E., Brunt, E. M., Wilson, L. A., Behling, C., Guy, C., Contos, M., Cummings, O., Yeh, M., Gill, R., Chalasani, N., et al. (2019) · JAMA Network Open

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 372

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

The UK-PSC Consortium, Ji, S.-G., The International IBD Genetics Consortium, The International PSC Study Group, Juran, B. D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., Kumasaka, N., et al. (2017) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 357

Risk Factors for Idiosyncratic Drug-Induced Liver Injury

Chalasani, N., & Björnsson, E. (2010) · Gastroenterology

Drug-Induced Hepatotoxicity and ProtectionDrug-Induced Adverse Reactions

Cited by 347

Systemic Levels of Lipid Peroxidation and Its Metabolic and Dietary Correlates in Patients with Nonalcoholic Steatohepatitis

Chalasani, N., Deeg, M. A., & Crabb, D. W. (2004) · The American Journal of Gastroenterology

Antioxidant Activity and Oxidative StressLiver Disease Diagnosis and Treatment

Cited by 343

High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population

Vilar‐Gomez, E., Nephew, L. D., Vuppalanchi, R., Gawrieh, S., Mladenovic, A., Pike, F., Samala, N., & Chalasani, N. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentNutritional Studies and Diet

Cited by 277

IL-12/Th1 and IL-23/Th17 Biliary Microenvironment in Primary Biliary Cirrhosis: Implications for Therapy

Yang, C.-Y., Ma, X., Tsuneyama, K., Huang, S., Takahashi, T., Chalasani, N. P., Bowlus, C. L., Yang, G.-X., Leung, P. S. C., Ansari, A. A., et al. (2014) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 213

A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation

Vujkovic, M., Ramdas, S., Lorenz, K. M., Guo, X., Darlay, R., Cordell, H. J., He, J., Gindin, Y., Chung, C., Myers, R. P., et al. (2022) · Nature Genetics

Liver Disease Diagnosis and TreatmentGenetic Associations and Epidemiology

Cited by 205

Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis

Vilar‐Gomez, E., Vuppalanchi, R., Gawrieh, S., Ghabril, M., Saxena, R., Cummings, O. W., & Chalasani, N. (2020) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 193

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

Cordell, H. J., Fryett, J. J., Ueno, K., Darlay, R., Aiba, Y., Hitomi, Y., Kawashima, M., Nishida, N., Khor, S.-S., Gervais, O., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 182

Lipid-lowering agents that cause drug-induced hepatotoxicity.

Bhardwaj, S. S., & Chalasani, N. (2007) · Clinics in Liver Disease

Drug-Induced Hepatotoxicity and ProtectionLiver Disease Diagnosis and Treatment

Cited by 173

Treatment with LY 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Guzman, C. B., Zhang, X. M., Liu, R., Regev, A., Shankar, S., Garhyan, P., Pillai, S. G., Kazda, C., Chalasani, N., & Hardy, T. A. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 172

Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report

Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology

Drug-Induced Hepatotoxicity and ProtectionLiver Diseases and Immunity

Cited by 166

Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes

Vuppalanchi, R., Chalasani, N., & Teal, E. (2005) · The American Journal of the Medical Sciences

Drug-Induced Hepatotoxicity and ProtectionLiver Disease Diagnosis and Treatment

Cited by 133